Part of Search Engine Optimization - getting a website to the top in the search rankings - is creating articles about the website that appear elsewhere on the web. This means blog posts, reviews, and media-friendly articles that mention the site and the business in a positive way, and also that realistically contain certain search keywords, so that when people type those keywords into a search engine, the site, and the business, show up at the top of the search rankings for those specific, targeted keywords.
In this case, the assignment was combined with a request that the articles directly market the organization from a third-party perspective.
__________
The Experts in Ophthalmic Contract Research
For both in vivo and in vitro retinal disease models and retinopathy preclinical efficacy trials, EyeCRO are the new state of the art. Their use of laser technology and rigorous pharmacokinetics for consistent and reliable results is nothing short of amazing. I am very impressed by their ability to study, model, and test treatments for vascular permeability of the retina, as well as issues arising from degeneration of the retina and ocular angiogenesis. This rigorous and disciplined quality lies behind their skills in formulation of eye drops, depot forming injectables, microparticles, fluorescent micro and nanoparticles, and PLGA nanoparticles. Their use of FDA approved polymers to enable vitreous injection is cutting edge clinical science made real, and truly useful, taking lab results past preclinical application, and into the lives of your patients. These formulations remain in the injection site, allowing the polymer to diffuse away leaving behind a depot of the drug which slowly diffuses from depot to the retina for sustained delivery for several days. This kind of forward thinking technology is the product of rigorous study of cell cycle and apoptosis enhanced by use of flow cytometric analysis tools such as ModFit LT (Verity Software). These and other technologies take EyeCRO beyond the mere formulation of lab proven compounds, and into the truly useful real world of treatment of patients for retinal and ocular disease and degeneration. My take away from all of this is that EyeCRO is the leading edge.
__________
Eye-opening Ophthalmic Research
EyeCRO is composed of an internationally recognized team of research scientists focused on ophthalmic disease. The company, founded in 2005 with a contract to study the effects of one of the world’s largest pharmaceutical company’s drugs in an animal model, has only grown. EyeCRO started as a way to support the drug pipeline of a small pharmaceutical company, but quickly turned into a thriving business of its own, with a specialization in retinopathy, pharmacokinetics research, preclinical efficacy trials, and advanced laser technology. In short, no one knows the retina and advanced treatments and formulation better then the experts at EyeCRO. With their associated backgrounds in formulation, study design, ocular surgery, veterinary, cell biology and molecular biology, they bring a uniquely evolved mixture of expertise to the table for advanced therapies and compound testing and formulation. Their association with the University of Oklahoma Health Sciences Center allows EyeCRO to keep its costs down, while still providing the knowledge and competency to provide an exceptional product in a timely manner, leaving them the best solution for quick, budgetary services in the field of formulation of eye drops, depot forming injectables, microparticles, fluorescent micro and nanoparticles, PLGA nanoparticles, as well as depot forming injectables, just to name a few. The team at EyeCRO is constantly redefining what it means to be at the forefront of in vitro and in vivo preclinical efficacy testing and research, with reliable results and innovative techniques such as FDA approved polymers in vitreous depot delivery, and many other advanced technologies.
__________
Keeping an Eye Out for the Best Contract Research
EyeCRO provides consultation to design an appropriate study for your goals and objectives, has a long history of completing projects on time and under budget, and sets itself apart from the large CRO’s through customer service and attention to detail. EyeCRO has fielded the most balanced team of specialists in veterinary medicine, retinopathy, pharmacokinetics, and formulation of unique delivery systems for vitreous delivery and retina treatment, and they bring this expertise to preclinical efficacy trials for advanced ophthalmic formulation and delivery. The use of every level of technology and study from laser tech to utilizing a combination of formulation proficiency and historical awareness of vehicle suitability, they ensure a lead candidate selection process and a formulation suitable for your preclinical needs. No one knows this process better than EyeCRO, and the subtleties of development needs are not lost on them – far from it. The deep knowledge of physiochemical drug characteristics, the rigorous application preformulation screens prior to formal formulation development experiments, and the vast expertise in efficacy testing make them, far and away, the foremost experts in their field. The development and production of nanoparticles in the 100-300 nm range applied to proprietary technology for incorporating hydrophobic drugs allows these scientists to tailor drug loading from 10% to 40%, and create in vitro release profiles that extend for as long as six months! And this is just scratching the surface of their capabilities. This is tech that has to be seen to be believed.
__________
A Company to Look Out For
Watching EyeCRO! When you look for the best in contract research, you want to see the highest of high tech capabilities. Testing the preclinical efficacy and pharmacokinetics of polymer based drug depots for the retina is not for the faint of heart, and it isn’t your grandma’s ophthalmic test beds. Only the most capable, only the most advanced team of multifield experts is going to cut it. In vitro and in vivo testing of retinopathy treatments is serious science, and I want to see capabilities down to the 100 nm range for nanoparticle synthesis and formulation, I want to see advanced polymer capabilities, and treatments that continue to deliver way past a window of a few days or weeks, I want to see long term delivery curves, out to six months. Picking a CRO is serious business, and choosing a team for development of treatments for vitreous and retinal issues requires vision at a level of granularity that is rare, if not unheard of. You want to see that your team has not only the ability to formulate workable treatments, but to formulate the proper preclinical trials to validate those treatments, and then the historical awareness of vehicle suitability, to ensure a lead candidate selection process and a formulation suitable for your needs. When you’re looking for serious expertise in incorporated hydrophobic drugs with the ability to tailor the drug loading from 10% to 40% w/w, you actually don’t have to look very far. When I want to see excellence in ophthalmics, I look at EyeCRO.
__________
EyeCRO Shows 20/20 Vision
Let’s face it, choosing the wrong contract researcher is short-sighted. Testing the preclinical efficacy and pharmacokinetics of polymer based drug depots for the retina takes serious scientific chops, and a level of expertise that is hard to find. How many researchers and formulation experts can you name that work down to the 100 nm range in nanoparticle production? There just plain aren’t that many out there. And when you narrow that search down to those that have an ophthalmic specialty, the field of view becomes vanishingly small. And in that very small, very hard-to-find group of top-notch specialists, you have to make a choice. You have to look closely at your options. Things to look for? How about treatments that continue to deliver way past a window of a few days or weeks, but long term delivery curves, out to six months? How about singular expertise in the use of FDA approved polymers for vitreous depots? And I think that microparticles designed to stay in the vitreous and release the drug, plus nanoparticles designed to enter cells directly and release the drug intracellularly are key indicators that you’re dealing with the cutting edge of the leading experts in their field. Basically, there is only one contract researcher out there that not only has the grasp of technologies from laser to fluorescent micro- and nanoparticles with sizes of 100 to 300 nm, 5um and 30um, but has the relationships with university labs to keep costs down, and the history of coming in on time and under budget. EyeCRO is clearly in focus, and the search is over.